To hear about similar clinical trials, please enter your email below
Trial Title:
Online Adaptive Radiation Therapy for Rectal Cancer
NCT ID:
NCT05911789
Condition:
Rectal Cancer
Conditions: Official terms:
Rectal Neoplasms
Conditions: Keywords:
rectal cancer
adaptive radiation therapy
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
Online adaptive radiation therapy
Description:
A dose of 45Gy will be delivered to planning target volume (PTV)
Arm group label:
Online adaptive radiation therapy
Other name:
ART
Summary:
In the present study, the investigators will evaluate the efficacy, toxicities, and of
online adaptive radiation therapy (ART) for patients with rectal cancer treated with
neoadjuvant chemoradiotherapy.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. ≥18 years old;
2. Diagnose with rectal cancer;
3. T3-T4 or N+, and no distant metastasis
4. Neoadjuvant chemoradiotherapy intended;
5. Surgery is expected after neoadjuvant therapy;
6. ECOG score 0-2, expected to lie in the treatment bed for at least half an hour;
Exclusion Criteria:
1. With contraindications to rectal MRI;
2. Received surgery, radiotherapy or chemotherapy for rectal cancer;
3. History of pelvic radiotherapy.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
August 5, 2023
Completion date:
June 1, 2025
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05911789
